Yes, Seroquel (quetiapine) can cause confusion in elderly patients.
Quetiapine is explicitly recognized as sedating and capable of causing delirium (confusion) in older adults, particularly when used at higher doses or in vulnerable populations. 1 The 2018 ESMO guidelines specifically note that "antipsychotics and benzodiazepines can themselves cause increased patient agitation and delirium" 1, and quetiapine is listed among medications that may paradoxically worsen confusion rather than improve it.
Key Evidence on Confusion Risk
The FDA drug label for Seroquel warns about "somnolence or sedation (which may lead to falls)" and advises caution about "performing any activity requiring mental alertness." 2 While the label doesn't explicitly use the word "confusion," it emphasizes cognitive impairment risks, particularly during initial dosing.
The 2021 Mayo Clinic polypharmacy guidelines classify quetiapine among atypical antipsychotics that should be avoided or tapered in elderly patients with cognitive behavioral problems, noting they "worsen cognitive function in dementia." 3 The 2019 AGS Beers Criteria similarly caution about antipsychotics in older adults, though quetiapine receives some exceptions for specific conditions like Parkinson's disease psychosis. 4
Mechanism and Clinical Context
Quetiapine causes confusion through multiple mechanisms:
- Sedation: The ESMO guidelines consistently describe quetiapine as "sedating" 1
- Orthostatic hypotension and dizziness: These effects can lead to cerebral hypoperfusion and secondary confusion 1
- Anticholinergic properties: Research indicates quetiapine has weak anticholinergic effects that can impair cognition, particularly in patients with pre-existing cholinergic deficits like Alzheimer's disease 5
Comparative Safety Data
Recent research (2025) demonstrates quetiapine's significant cognitive risks in elderly patients. A retrospective cohort study of 375 older adults using low-dose quetiapine for insomnia found dramatically increased rates of dementia compared to trazodone (HR 8.1,95% CI 4.1-15.8) and mirtazapine (HR 7.1,95% CI 3.5-14.4). 6 This suggests even low doses carry substantial cognitive risk.
A 2025 systematic review on severe agitation management found quetiapine had the lowest frequency of adverse events among antipsychotics studied (OR 0.27 compared to haloperidol), though this was in the context of acute agitation management rather than chronic use. 7
Dosing Considerations to Minimize Risk
When quetiapine must be used in elderly patients, the ESMO guidelines recommend:
- Starting dose: 25 mg immediate-release orally 1
- Dosing frequency: Every 12 hours if scheduled dosing required
- Critical instruction: "Reduce dose in older patients and patients with hepatic impairment" 1
The 2002 Alzheimer's disease guidelines suggest even lower starting doses (12.5 mg twice daily) with a maximum of 200 mg twice daily, noting quetiapine is "more sedating" and warning to "beware of transient orthostasis." 8
Common Pitfalls to Avoid
Assuming low doses are safe: The 2025 study demonstrates that even low-dose quetiapine (used for insomnia) significantly increases dementia risk in older adults 6
Ignoring the paradox: Quetiapine may be prescribed to manage confusion/delirium but can actually worsen it 1
Overlooking drug interactions: Quetiapine has no significant cytochrome P450 interactions compared to other antipsychotics, but its sedative effects compound with other CNS depressants 1
Failing to monitor: The 2016 systematic review found somnolence (25-39%), dizziness (15-27%), and cognitive impairment were among the most common adverse events in elderly patients 9
When Quetiapine May Be Considered Despite Risks
Quetiapine receives specific exceptions in:
- Parkinson's disease psychosis (along with clozapine and pimavanserin) 4
- Severe agitation where non-pharmacologic approaches have failed and patient/staff safety is at immediate risk 1
- Delirium management when perceptual disturbances are present, using PRN dosing at the lowest effective dose for the shortest time possible 1
However, even in these scenarios, the risk of worsening confusion must be weighed against potential benefits, and non-pharmacologic interventions should always be attempted first.